17,300 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Bought by Natixis Advisors LLC

Natixis Advisors LLC bought a new stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 17,300 shares of the company's stock, valued at approximately $403,000.

Several other large investors also recently modified their holdings of SYRE. Mirae Asset Global Investments Co. Ltd. bought a new position in Spyre Therapeutics during the fourth quarter valued at $46,000. Quest Partners LLC lifted its position in shares of Spyre Therapeutics by 271.2% during the 3rd quarter. Quest Partners LLC now owns 5,654 shares of the company's stock valued at $166,000 after buying an additional 4,131 shares during the last quarter. Arizona State Retirement System grew its stake in shares of Spyre Therapeutics by 38.4% during the 4th quarter. Arizona State Retirement System now owns 10,115 shares of the company's stock worth $235,000 after acquiring an additional 2,805 shares during the period. Intech Investment Management LLC purchased a new stake in Spyre Therapeutics in the 3rd quarter worth about $246,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in Spyre Therapeutics in the 4th quarter valued at about $290,000. Hedge funds and other institutional investors own 80.39% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on SYRE shares. The Goldman Sachs Group upgraded shares of Spyre Therapeutics to a "strong-buy" rating in a research report on Tuesday, February 18th. Wedbush reaffirmed an "outperform" rating and issued a $65.00 price objective on shares of Spyre Therapeutics in a report on Monday, January 13th. Finally, Wolfe Research began coverage on Spyre Therapeutics in a research report on Tuesday, March 18th. They set an "outperform" rating and a $27.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $50.33.

Spyre Therapeutics Stock Performance

NASDAQ SYRE traded down $1.80 on Monday, hitting $16.14. The stock had a trading volume of 740,838 shares, compared to its average volume of 556,890. The firm has a 50-day moving average of $20.45 and a 200-day moving average of $25.47. The company has a market capitalization of $972.55 million, a price-to-earnings ratio of -2.16 and a beta of 2.98. Spyre Therapeutics, Inc. has a 52-week low of $16.14 and a 52-week high of $40.84.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.08. As a group, research analysts anticipate that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current fiscal year.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).